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CHK2 overexpression and mislocalisation within
mitotic structures enhances chromosomal instability
and hepatocellular carcinoma progression
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Tu Vinh Luong,4 Massimo Pinzani,5 Krista Rombouts,5 Andrea Galli3
ABSTRACT
Objective Chromosomal instability (CIN) is the most
common form of genomic instability, which promotes
hepatocellular carcinoma (HCC) progression by
enhancing tumour heterogeneity, drug resistance and
immunity escape. CIN per se is an important factor of
DNA damage, sustaining structural chromosome
abnormalities but the underlying mechanisms are
unknown.
Design DNA damage response protein checkpoint
kinase 2 (Chk2) expression was evaluated in an animal
model of diethylnitrosamine-induced HCC characterised
by DNA damage and elevated mitotic errors. Chk2 was
also determined in two discrete cohorts of human HCC
specimens. To assess the functional role of Chk2, gain
on and loss-of-function, mutagenesis, karyotyping and
immunofluorescence/live imaging were performed by
using HCT116, Huh7 and human hepatocytes
immortalised with hTERT gene (HuS).
Results We demonstrate that mitotic errors during HCC
tumorigenesis cause lagging chromosomes/DNA damage
and activation of Chk2. Overexpression/phosphorylation
and mislocalisation within the mitotic spindle of Chk2
contributes to induce lagging chromosomes. Lagging
chromosomes and mitotic activity are reversed by
knockdown of Chk2. Furthermore, upregulated Chk2
maintains mitotic activity interacting with Aurora B
kinase for chromosome condensation and cytokinesis.
The forkhead-associated domain of Chk2 is required for
Chk2 mislocalisation to mitotic structures. In addition,
retinoblastoma protein phosphorylation contributes to
defective mitoses. A cohort and independent validation
cohort show a strong cytoplasm to nuclear Chk2
translocation in a subset of patients with HCC.
Conclusions The study reveals a new mechanistic
insight in the coinvolvement of Chk2 in HCC progression.
These findings propose Chk2 as a putative biomarker to
detect CIN in HCC providing a valuable support for
clinical/therapeutical management of patients.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the primary
malignancy of hepatocytes and the most frequent
solid tumour of the liver. Half a million cases occur
annually and the WHO has recently ranked HCC
as the second most lethal cancer worldwide.1
Different aetiological factors such as hepatitis B
Significance of this study
What is already known on this subject?
▸ Chromosomal instability (CIN) is a major
hallmark of hepatic tumorigenesis and hampers
prognosis and therapy. The underlying
mechanisms are not well characterised.
▸ CIN is regarded as an ongoing elevated
frequency of mitotic errors that leads to
numerical and structural chromosome
aberrations in a significant proportion of cell
divisions leading to intratumoural heterogeneity
and drug resistance.
▸ DNA damage caused by genotoxic agents
activates DNA damage response checkpoint
kinase 2 (Chk2) protein expression.
▸ Mislocalisation of proteins, including
oncoproteins, tumour suppressors and other
cancer-related proteins, can interfere with
normal cellular function and cooperatively drive
tumour development.
What are the new findings?
▸ Mitotic errors represented by lagging
chromosomes cause DNA damage and
overexpress Chk2 throughout hepatic
tumorigenesis.
▸ Chk2 and the activation/phosphorylated forms
of Chk2 mislocalise within the mitotic
structures in the presence of DNA damage
contributing to increased numbers of cells
with lagging chromosomes. In contrast,
knockdown of Chk2 reduces the number of
cells with lagging chromosomes and the
mitotic index.
▸ The Chk2 forkhead-associated domain is
responsible for the mislocalisation of the
protein at the mitotic structures.
▸ Chk2 is expressed at the nuclear level in a
subset of human hepatocellular carcinoma
(HCC) and this aspect correlates with HCC
progression. Moreover, CHK2 expression is
significantly higher in patients with HCC with
mutated TP53, a hallmark of genomic
instability, than in those with mutated
CTNNB1/β-catenin.
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and C virus, alcohol and diabetes cause liver injury followed by
inflammation, necrosis and hepatocytes proliferation.2
Continuous cycles of this destructive–regenerative process cul-
minates in liver cirrhosis which is characterised by regenerating
nodules that progress to dysplastic nodules and ultimately
HCC.3 4 More than 90% of HCC, including dysplastic nodules
in cirrhotic liver, possess chromosomal aberrations suggesting
that chromosomal defects occur at early stages of tumour devel-
opment and several attempts have been made to connect differ-
ent chromosomal aberration patterns as specific subsets of
HCC, although with limited success.5–7 A common feature of
human HCC and dysplastic nodules is represented by chromo-
somal instability (CIN). Various types of chromosomal aberra-
tions, including numerical (aneuploidy) and structural (eg,
translocations, deletions), are found in HCC and are linked to
tumorigenesis.8 9 An important aspect in studying HCC tumori-
genesis is to distinguish between the state of the karyotype and
the rate of karyotypic change. In fact, aneuploidy is not syn-
onymous with CIN, because aneuploid tumours are stable with
uniform karyotype and phenotype.10–12 Conversely, there is an
increased rate of CIN generating diverse karyotypes within the
same tumour. This yields a heterogeneous tumour cell popula-
tion that has the ability to undergo selective evolution in term
of drug resistance and immune system escape mechanisms.13–15
CIN is regarded as an ongoing elevated frequency of mitotic
errors that leads to additional chromosome gains or losses in a
significant proportion of cell divisions. Our hypothesis is that
CIN per se is also an important mechanism of DNA damage
inducing structural chromosome aberrations in HCC. To verify
this hypothesis, we used checkpoint kinase 2 (Chk2) as a central
effector of the cell response to DNA damage. In fact, Chk2 has
been described to detect a variety of DNA lesions caused by
exogenous and endogenous genotoxic agents. Our aim is to
investigate the expression of this kinase in hepatic carcinogenesis
and its correlation with the genesis of structural chromosomal
aberrations. Here, we provide evidence that defective chromo-
some segregation, that is, lagging chromosomes cause DNA
damage and determine an overexpression/phosphorylation of
Chk2. Furthermore, the mislocalisation of Chk2 with compo-
nents of the mitotic spindle contributes to chromosome misse-
gregations. These data are corroborated with the observation of
an increased Chk2 and nuclear translocation in two independ-
ent cohorts of human HCC specimens.
MATERIALS AND METHODS
Please refer to the online supplementary materials and methods
for more detailed descriptions.
Tissue samples and immunohistochemistry assays
Florence cohort, University Hospital of Florence: formalin-fixed,
paraffin-embedded tissues were obtained from an archive of
liver biopsies of patients diagnosed with HCC. H&E-stained
tissue sections of 49 patients were reviewed, and areas of cir-
rhotic and HCC were identified. Chk2 antigen retrieval was per-
formed by heating in citrate buffer pH 6.0 at 98°C for 30 min.
Non-specific signal was eliminated by peroxidase block for
10 min at room temperature. Primary antibody was incubated at
room temperature overnight in a humidified chamber followed
by Horseradish peroxidase (HRP)-conjugated secondary antibody
incubation for 30 min at room temperature. Antibody binding
was revealed by 3,30-Diaminobenzidine and reaction was stopped
by immersion of tissue sections in distilled water once brown
colour appeared. Tissue sections were counterstained by haema-
toxylin, dehydrated in graded ethanols and mounted. All reagents
for immunohistochemistry were from Dako. Appropriate positive
and negative controls were included for each run of immunohis-
tochemistry. Chk2 expression was determined according to
H-score method. For H-score assessment, 10 fields were chosen
at random at ×400 magnification and the staining intensity in
the malignant cell nuclei was scored as 0, 1, 2 and 3 correspond-
ing to the presence of negative, weak, intermediate and strong
brown staining, respectively. The total number of cells in each
field and the number of cells stained at each intensity were
counted. The average percentage positive was calculated, and a
H-score between 0 and 300 was obtained where 300 was equal
to 100% of tumour cells stained brown strongly. The positive
cut-off was considered ≥100 (see online supplementary figure
S1). Chk2 expression in biopsy sections was scored by a patholo-
gist and two researchers independently.
London cohort, Royal Free Hospital: formalin-fixed,
paraffin-embedded surgical specimens from consecutive patients
diagnosed with HCC were retrieved from Royal Free Hospital
archives. All samples were stained with H&E and the sections
were reviewed and suitable areas of cirrhosis and HCC were
identified in 20 samples. Antigen retrieval was performed by
microwaving (720 W) in pH 6.0 sodium citrate buffer for 30
min. Endogenous peroxidase and non-specific binding of primary
antibody was blocked. The primary Chk2 antibody was incu-
bated overnight at 5°C. Primary antibody detection was carried
out using the Novolink polymer detection system (Novocastra).
Tissue sections were counterstained with Mayer’s haematoxylin.
Experimental hepatocarcinogenesis
Twenty-five female Wistar rats (210–225 g) were given diethylni-
trosamine 50 mg/L ad libitum in their drinking water for a
period of 10 weeks as previously described.16 Another group of
five animals were maintained as controls. All animals were admi-
nistered a standard laboratory diet and were weighed each
week. Five animals for each time point were sacrificed on week
4, 6, 8, 10 and 14. Tumours and liver tissues were removed and
fixed in 10% neutral buffered formalin. Liver sections (5 mm)
were cut from paraffin-embedded blocks and stained Chk2
(Abcam, #ab47433), phospho-Histone H2A.X (Cell Signaling,
#9718) and H&E for histological examination and expression
were determined according to H-score method.
CHK2 expression in HCC samples from The Cancer Genome
Atlas database
The Cancer Genome Atlas (TCGA)-Liver Hepatocellular
Carcinoma (LIHC) cohort, containing 377 cases, was used to
validate CHK2 expression levels in distinct subtypes of HCC.
Significance of this study
How might it impact on clinical practice in the
foreseeable future?
▸ The study reveals a new mechanistic insight in the
coinvolvement of Chk2 in CIN, that is, Chk2 mislocalisation,
hence indicating the possibility to use Chk2 as a new drug
target in HCC.
▸ The findings of this study suggest Chk2 as a putative
biomarker that can be used to detect DNA damage and
chromosomal instability in HCC providing a valuable support,
for prognosis, and for identifying patients who are likely to
have a response to therapy.
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The TCGA database (https://gdc-portal.nci.nih.gov) was accessed
on 16 November 2016 through the cGbioportal website (http://
www.cbioportal.org/) to retrieve patients with either TP53 or
CTNNB1 mutation. The TCGA_participant_barcode was used
to download CHK2 expression from RNA-seq data using the
firebrowse portal (http://firebrowse.org). Patients with
co-occurrent mutations of TP53 and CTNNB1 were excluded
from the analysis. CHK2 expression levels were retrieved for
101 patients with TP53 mutation and 85 patients with
CTNNB1 mutation. Statistical analysis was performed using the
Mann-Whitney test with GraphPad 6 software.
RESULTS
Chk2 is overexpressed in a subset of human HCC
To test our hypothesis that hepatic tumorigenesis per se could
be a cause of DNA damage and structural chromosome aberra-
tions, an animal model of diethylnitrosamine-induced HCC was
employed which induced macroscopical visible tumours after
14 weeks (figure 1A). This model has previously been estab-
lished to induce elevated mitotic errors, DNA damage and
chromosome aberrations.17 Using this model, we can compare
the expression levels of DNA damage response proteins induced
by the genotoxic activity of diethylnitrosamine with a later
phase represented exclusively by tumorigenesis. Therefore,
Chk2, a DNA damage response checkpoint kinase, and
phospho-Histone H2A.X (Ser139), a component of chromatin
which becomes phosphorylated following DNA damage (eg,
DNA double-stranded breaks), were investigated.18 As shown in
figure 1B, several nuclei of cancer cells exhibited an increased
expression of Chk2 and phospho-Histone H2A.X revealing the
presence of DNA damage. A timeline analysis of liver sections
demonstrated a twofold increase in Chk2 basal levels at 4 weeks
followed by decreased values after 8 weeks (figure 1C). In con-
trast, by 14 weeks tumours were macroscopically visible and his-
tologically evident in 80% of animals. Immunostaining of HCC
sections showed a significant increased expression of Chk2 and
phospho-Histone H2A.X (figure 1C, D) when compared with
liver sections without evidence of tumours (8 weeks). Taken
together, these data showed that the increased expression of
Chk2 reflected a response triggered by DNA damage during
tumorigenesis.
To extend these findings to humans, the expression of Chk2
in patients with cirrhotic-related HCC and normal liver was
examined in liver biopsies from hospital archives (Florence
cohort, see online supplementary table S1). A nuclear staining
of Chk2 was detectable in distinctive histotypes of HCC (see
online supplementary figures S2 and S3). More specifically, the
expression level of Chk2 in different grades of HCC was evalu-
ated. Remarkably, within histological grades 2 and 3, significant
quantitative differences between positive and negative Chk2
patients were found (p<0.001). Overall, these data demon-
strated that Chk2 nuclear positivity was found in 63.2% (31 of
49) of HCCs analysed (see online supplementary table S2). A
separate validation cohort of patients was examined at Royal
Free Hospital, London (see online supplementary table S3).
Normal liver tissue showed a moderate and diffuse cytoplasmic
staining, whereas grade 1 specimens were characterised with
weak focal cytoplasmic Chk2 staining. In grade 2, a Chk2 peri-
nuclear and nuclear accumulation was observed. Specimens with
grade 3 showed exclusively a clear and strong nuclear staining,
Figure 1 Immunohistochemical
detection of checkpoint kinase 2
(Chk2) and phospho-Histone H2A.X
(Ser139) in diethylnitrosamine-induced
hepatocellular carcinoma (HCC). (A)
Representative image of livers of
female Wistar rats used as control (left
panel) and rats HCC (right panel)
which were given diethylnitrosamine
50 mg/L ad libitum in their drinking
water for a period of 10 weeks. Scale
bar, 10 mm. (B) Liver sections (HCC
14 weeks) were analysed for Chk2 and
phospho-Histone H2A.X(Ser139)
expression (see nuclear staining in the
right panels; scale bar, 200 mm.). (C
and D) Five animals for each time
point were sacrificed on weeks 4, 6, 8,
10 and 14. Chk2 and phospho-Histone
H2A.X(Ser139) expression were
determined according to H-score
method. The average positive
percentage was calculated, and a
H-score between 0 and 300 was
obtained where 300 was equal to
100% of tumour cells stained brown
strongly. The positive cut-off was
considered ≥100. The levels of Chk2
and phospho-Histone H2A.X(Ser139)
expression are indicated as fold
increase of cut-off values.*p<0.001
versus 8 weeks. Chk2 expression was
evaluated in the nucleus of the HCC
tissue as indicated by the brown
staining.
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without cytoplasmic and perinuclear Chk2 staining (figure 2A
and see online supplementary table S4). Furthermore, the
expression levels of CHK2 were analysed in a public available
cohort of HCC from the TCGA database. We found a highly
significant increase of CHK2 expression in HCC with mutated
TP53, a hallmark of genomic instability, with respect to those
with CTNNB1/β-catenin mutation (figure 2B).
Defective chromosome segregations cause DNA damage
The previous observations prompted us to investigate the func-
tional role of Chk2. For this reason, three different cell lines
were employed. The colon carcinoma cell line HCT116 was
used, that is, a near-diploid cell line that faithfully segregates
chromosomes to maintain a stable karyotype and is commonly
employed in CIN studies.19 20 Second, the HCC cell line Huh7
was used which is a stable hyperdiploid karyotype with altered
chromosomal structures, and finally HuS cells were used
marked with an unstable karyotype.21 HuS cells are human
hepatocytes immortalised with human telomerase reverse tran-
scriptase (hTERT), a gene described commonly activated in
human HCC.8 9 HuS cells just established in culture (0 gener-
ation) and hereafter referred to as HuS0gen showed a karyotype
Figure 2 (A) Detection of checkpoint kinase 2 (Chk2) protein in human hepatocellular carcinoma (HCC) by immunohistochemistry.
Paraffin-embedded tissue sections were stained with a specific antibody for Chk2 and H&E. (A) Normal liver with a moderate, diffuse cytoplasmic
Chk2 staining. (B) Chk2 immunoreactivity in cancer tissue from a tumour classified grade 1 characterised by a weak focal cytoplasmic Chk2 staining.
(C and D) Chk2 immunoreactivity in cancer tissue from a tumour classified grade 2 with a strong Chk2 perinuclear and moderate nuclear
accumulation. (E) Chk2 immunoreactivity in cancer tissue from a tumour classified grade 3 with a clear and strong nuclear staining, without
cytoplasmic and perinuclear Chk2 staining. Scale bar, 100 mm. (B) CHK2 expression in HCC subtypes from The Cancer Genome Atlas database.
CHK2 expression from RNA-seq data was retrieved for 101 patients with TP53 mutations and 85 patients with CTNNB1/β-catenin mutations, using
the Liver Hepatocellular Carcinoma (LIHC) cohort of 377 cases (accessed on 16 November 2016). Patients with both TP53 and CTNNB1 mutations
were excluded from the analysis. Expression levels are expressed as log2exp (absolute levels) or z-score (expression levels in HCC samples
normalised to the expression levels in the reference population). Graph shows mean±SEM, *p<0.0001.
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with a distribution of 46 chromosomes (figure 3A) and
expressed low levels of Chk2 protein in comparison to
HCT116 and Huh7 (figure 3B). The HuS0gen cells were main-
tained in culture and after 30 consecutive generations
(HuS30gen) were re-examined to verify the karyotype status.
The cells showed a distribution near triploid, with many struc-
tural chromosomal defects (figure 3C and see online
supplementary figure S4A), and importantly this aspect was
associated with increased expression of Chk2 protein (figure
3B). Likewise with the murine model, we evaluated the expres-
sion levels of phospho-Histone H2A.X (Ser139) in all the cell
lines studied. As shown in figure 3D, both HuS0gen and
HuS30gen cells exhibited high levels of phospho-Histone H2A.
X, although with different levels of expression. These findings
indicate the presence of DNA double-strand breaks, a hallmark
of DNA damage, in HuS cells.
Overexpressed Chk2 mislocalises with mitotic structures in
HuS30gen cells but not in HCT116 and Huh7
The finding of overexpressed Chk2 in both karyotyped stable
HCT116 and Huh7 and in unstable karyotyped HuS30gen did
not demonstrate a specific role for Chk2 in defective chromo-
some segregation. Therefore, we analysed the cell lines
HCT116, Huh7, HuS0gen and HuS30gen by immunofluores-
cence to examine a possible altered localisation of Chk2 with
the mitotic structures. Chk2 showed a localisation to the spindle
poles of metaphase mitotic structures in HCT116, Huh7 and
HuS0gen (figure 4A). Very importantly, HuS30gen cells showed
a robust localisation of Chk2 with all metaphase mitotic struc-
tures indicating a clear mislocalisation of Chk2 (figure 4A and
see online supplementary figure S4B). These results suggest that
in HuS0gen cells, expressing low levels of DNA damage, Chk2
weakly colocalised with the mitotic spindle components,
whereas Chk2 is increased and strongly associated with all
mitotic structures in HuS30gen cells that are expressing high
levels of DNA damage. To further address these findings, we
stably transfected HuS0gen with hemagglutinin (HA)-tagged
Chk2, HuS0gen overexpressing Chk2 exhibited Chk2 localisa-
tion with mitotic structures as shown in figure 4B. Next, we
measured the number of lagging chromosomes (figure 4C) in
HuS0gen, HuS30gen and in HuS0gen stably transfected with
HA-tagged Chk2 to mimic overexpression of Chk2. As shown
Figure 3 Defective chromosome
segregation causes checkpoint kinase
2 (Chk2) overexpression in hTERT
immortalised human hepatocytes. (A)
Examples of chromosome numbers
from metaphase spreads of HCT116,
Huh7 and HuS0gen cells (upper
panels). In the bottom panels,
individual chromosome numbers
percentage from metaphase spreads of
HCT116, Huh7 and HuS0gen cells are
represented (n=20). (B) Representative
immunoblot out of three independent
experiments demonstrating the protein
levels of Chk2 in indefinite cultured
HCT116 and Huh7 cells, in HuS0gen
cells and HuS0gen cells after 30
generations in culture (HuS30gen). (C)
Example of chromosomes from
metaphase spreads of HuS30gen
exhibiting numerical and structural (red
arrow) alterations; the histogram
shows individual chromosome numbers
percentage in HuS30gen (n=20). (D)
Representative immunoblot out of
three independent experiments
demonstrating the protein levels of
phospho-Histone H2A.X (Ser139), a
hallmark of DNA damage, in indefinite
cultured HCT116, Huh7, HuS0gen and
HuS30gen cells.
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in figure 4D, overexpression of Chk2 significantly correlated
with high number of mitoses with lagging chromosomes in
HuS30gen, and in HuS0gen overexpressing HA-tagged Chk2.
These data clearly indicate that indeed overexpression and mis-
localisation of Chk2 itself contributes to defective chromosome
segregations. Furthermore, to assess that the increased expres-
sion of Chk2 was specifically related to those mitoses with
defective chromosome segregations and not a random deregula-
tion of proteins, the expression of Nek2 (NIMA-related kinase
2) protein was evaluated. Nek2 is a protein located at the
centrosome/spindle poles and responsible for chromosomal
defective segregations.22 HCT116 and Huh7 cells showed a
strong Nek2 expression, whereas both HuS0gen and HuS30gen
cells expressed low levels of Nek2 (see online supplementary
figure S5) suggesting that the previously observed overexpres-
sion of Chk2 in Hus30gen was a specific event that coincided
with structural chromosomal defects and DNA damage.
Chk2 overexpression is correlated with increased
chromosomal missegregations
The findings that HuS30gen cells express high levels of Chk2
protein correlating with DNA damage (figure 3B,D) prompted us
to investigate the effects of knocking down expression of CHK2 in
HuS30gen cells by retroviral-mediated short hairpin RNA
(shRNA) transduction. A pool of four shRNA targeting Chk2
resulted in effective decrease of the protein (figure 5A). It is
important to note that silencing CHK2 coincided with a significant
reduction of the number of HuS30gen cells with lagging chromo-
somes and HuS30gen mitotic index. To address any off-target
effects of the hairpins, we rescued the mitotic index and the
number of cell with lagging chromosomes of the knockdown
HuS30gen by expressing a myc-tagged version of Chk2 that cir-
cumvents the shRNA directed against human Chk2 (figure 5B,C).
These data demonstrate that Chk2 overexpression is correlated
with increased chromosomal missegregation and mitotic index.
Defective mitoses-related DNA damage promotes Chk2
phosphorylation and mislocalisation within mitotic
structures
Human CHK2 is a 543-amino-acid protein that consists of a
N-terminal SQ/TQ cluster domain (SCD), a central
forkhead-associated (FHA) domain and a C-terminal serine/
threonine kinase domain.23 The SCD consists of multiple SQ/
TQ (Ser-Gln/Thr-Gln) motifs with Thr68 being the primary site
to be phosphorylated in response to DNA damage followed by
phosphorylation of Thr387 in the activation loop of the kinase
domain.24 25 Therefore, the protein expression of phospho-
Thr68-Chk2 and phospho-Thr387-Chk2 in HuS30gen and
HuS0gen stably transfected with HA-tagged Chk2 were
assessed. As shown in figure 5D, phospho-Thr68-Chk2 and
phospho-Thr387-Chk2 were highly expressed in HuS30gen and
in HuS0gen stably transfected with HA-Chk2, but not in
HuS0gen as expected. Furthermore, phospho-Thr68-Chk2
revealed a robust localisation with components of the mitotic
spindle as previously shown for Chk2. In particular, a promin-
ent association of phospho-Thr68-Chk2 was observed with
mitotic structures such as the spindle poles, kinetochores and
midbody in Hus30gen cells (figure 5E, upper panels). In contrast,
Huh7 cells expressing low levels of DNA damage (see figure 3D)
did not show colocalisation of phospho-Thr68-Chk2 with mitotic
structures (figure 5E, lower panels). Taken together, these results
reveal an overexpression/mislocalisation of phosphorylated Chk2,
which is correlated with its activation status, and manifestations of
lagging chromosomes-induced DNA damage.
Upregulated Chk2 cooperates with Aurora B for
chromosome condensation and cytokinesis
As previously shown, the typical localisation of activated Chk2
in HuS30gen cells was observed in kinetochores and specifically
the midbody, suggesting a possible interaction with Aurora B
kinase. This protein is known to be involved in chromosome
condensation, the assembly of the spindle midzone in anaphase
and the midbody during telophase. Furthermore, Aurora B
kinase has been identified as an effective predictor of aggressive
HCC recurrence, in relation to genomic instability.26 Therefore,
HuS0gen cells were transfected with HA-tagged Chk2 and
immunofluorescence analyses revealed a colocalisation of Chk2
with Aurora B throughout all mitotic phases, and this colocalisa-
tion was also present in cells marked with lagging chromosomes
(figure 6A, B). Aurora B is responsible for the phosphorylation
of histone H3 (pHH3), and pHH3 serine residue (Ser-10) is
considered to be a crucial event for the onset of mitosis. The
utility of pHH3 to identify mitoses has been demonstrated in
several cancer studies.27–29 As the colocalisation of Aurora B
with Chk2 was demonstrated, we further explored the colocali-
sation of overexpressed HA-Chk2 with pHH3. As shown in
figure 6C, Chk2 exhibited a striking colocalisation with pHH3.
Overall, the data so far demonstrate that in unstable HuS cells
during mitosis, lagging chromosomes cause DNA damage, over-
expression of Chk2 which localises to all mitotic structures.
This overexpressed and mislocalised Chk2 protein contributes
to a constant mitotic activity and more important Aurora B
kinase and pHH3 interact with Chk2. This favours a possible
scenario where an overexpressed and mislocated Chk2 overrules
the signalling specificity at distinct mitotic checkpoints inducing
itself chromosomal aberrations, hence CIN.
The FHA domain determines Chk2 mislocalisation to mitotic
structures and is essential for DNA damage response
To understand how Chk2 is recruited to the mitotic structures
in such a specific manner, we investigated Chk2 specific domain
(s) that are required for Chk2 localisation. A series of red
Figure 4 Checkpoint kinase 2 (Chk2) overexpression is linked to lagging chromosomes. (A) Chk2 colocalises with chromosomal structures only in
HuS30gen cells. Asynchronously growing HCT116, Huh7, HuS0gen and HuS30gen cells were synchronised in metaphase by releasing cells from
thymidine treatment into MG132. Metaphase mitotic spindles were monitored by immunofluorescence and typical examples are given, endogenous
Chk2 (red); kinetochores, CENP-H (green); chromosomes are stained with Hoechst 33342 (blue). Chk2 colocalisation with chromosome structures
was quantified in metaphases (mean±SD; n≥ 300 metaphases). (B) HuS0gen cells that express low levels of protein Chk2 were stably transfected
with HA-tagged Chk2 and asynchronously growing cells were evaluated for lagging chromosomes; typical examples of lagging chromosomes
containing anaphase and telophase are given (HA-Chk2, red; CENP-H, green; chromosomes, Hoechst 33342, blue). (C) Asynchronously growing
HuS30gen cells expressing H2B-green fluorescent protein (GFP) (to visualise in vivo lagging chromosomes) were analysed by live cell microscopy.
Left, phase-contrast images; middle, fluorescence images; right, merge. Scale bar, 10 μm. (D) Asynchronously growing HCT116, Huh7, HuS0gen,
HuS30gen and HuS0gen cells stably transfected with HA-tagged Chk2 (HuS-Chk2) were stained with CENP-H (constitutive component of
kinetochores) and Hoechst 33342 (chromosomes). Anaphase and telophase lagging chromosomes were counted by immunofluorescence (mean±SD;
n=500 cells). *p<0.01 versus HuS0gen. **p<0.05 versus HuS-mock. CENP-H, centromere protein; HA, hemagglutinin.
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fluorescent protein (RFP)-tagged Chk2 variants were created,
each variant carrying a point mutation or a deletion, and were
expressed and localised individually in HuS30gen. The
RFP-Chk2D347A, a kinase-inactive mutant, localised similarly
as shown for RFP-Chk2 (figure 7A). This indicated that the
kinase activity is dispensable for Chk2 mislocalisation (figure
7B). The FHA domain of Chk2 has been proposed to mediate
localisation of Chk2 to mitotic structures for the reason that
FHA domains function as phospho-threonine-binding protein
motifs. The deletion of the Chk2 FHA domain disrupted the
localisation of the protein to mitotic structures such as the
spindle poles and kinetochores indicating that the deletion of
Figure 5 Overexpressed/
phosphorylated checkpoint kinase 2
(Chk2) is correlated with increased
chromosomal missegregation. (A)
HuS30gen cells were stably retrovirally
transduced either with a control
shRNA (shCTL) or shRNAs targeting
CHK2 (shChk2). Chk2-depleted
HuS30gen cells were used to
reconstitute expression of CHK2 by
introducing a shRNA-resistant mutant
of CHK2 (myc-Chk2resist). The protein
levels were determined by
immunoblotting and a representative
example is shown. (B) Asynchronously
growing HuS30-shCTL, HuS30-shChk2
and Chk2-depleted HuS30gen cells
reconstituted with shRNA-resistant
mutant of CHK2 were stained with
CENP-H (kinetochores) and Hoechst
33342 (chromosomes). Anaphase and
telophase lagging chromosomes
counted by immunofluorescence (mean
±SD; n=500 cells), *p<0.01versus
controls. (C) The mitotic index of
asynchronously growing HuS30-shCTL,
HuS30-shChk2 and Chk2-depleted
HuS30gen cells reconstituted with
shRNA-resistant mutant of CHK2 was
measured by counting the mitotic
figures (prophase, metaphase,
anaphase and telophase) positively
stained for phosphorylated histone H3.
The mitotic index was calculated as
percentage of mitotic cells/total cells
as described in the section ‘Materials
and Methods’. Error bars show the SD
from the means of three independent
experiments, *p<0.01versus controls.
(D) Chk2 phosphorylation levels on
Thr68 and Thr387. Representative
immunoblot out of three independent
experiments showing asynchronously
growing HCT116, HuS0gen, HuS30gen
and HuS0gen cells stably transfected
with Chk2 (HuS-Chk2). Cell lysates
were immunoblotted against
p-Thr68-Chk2 and p-Thr387-Chk2. (E)
Activated Chk2 localises with mitotic
structures in HuS30gen cells. Examples
of metaphase, anaphase and telophase
from unstable HuS30gen cells and
stable hepatocellular carcinoma cell
line, Huh7. Activated Chk2
(p-Thr68-Chk2, red) colocalises with
CENP-H, constitutive component of
kinetochores (green) only in
HuS30gen. Arrowheads indicate
lagging chromosomes (Hoechst 33342,
blue). Scale bar, 10 μm. CENP-H,
centromere protein.
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Figure 6 Upregulated checkpoint kinase 2 (Chk2) cooperates with Aurora B for chromosome condensation and cytokinesis. (A) HuS0gen cells
showing expression and localisation of endogenous Chk2 (red), Aurora B kinase (green) and chromosomes (Hoechst 33342, blue). (B) Colocalisation
of Aurora B kinase (green) with HuS0gen overexpressing HA-tagged Chk2 (red) in mitoses with lagging chromosomes (Hoechst 33342, blue). Cells
were fixed and analysed by fluorescence microscopy. Arrows indicate spindle midzone region; arrowheads indicate midbody region. (C) HuS0gen
cells overexpressing HA-tagged Chk2 were stained with antibody anti-HA (red) and phospho-histone H3 (green) to show colocalisation of Chk2 with
missegregating chromosomes. Scale bar, 10 mm. HA, hemagglutinin; pHH3, phosphorylated histone H3.
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Figure 7 Forkhead-associated (FHA) domain is essential for Chk2 localisation and contributes to sustain lagging chromosomes. Red fluorescent
protein (RFP) was conjugated at the N-terminus of each Chk2 mutant. Left, schematic diagrams. RFP was omitted. RFP-Chk2 mutants were
transfected in HuS30gen cells, synchronised and blocked in metaphase by treatment with MG132 for 2 hours; the cells were analysed by
fluorescence microscopy. (A) Expression and subcellular localisation of RFP-Chk2. RFP-Chk2 decorates the spindle poles (two red dots), and localises
with kinetochores (CENP-H, green); chromosomes are stained with Hoechst 33342, blue. (B) RFP-Chk2D347A, kinase dead mutant (KD), localises
similarly to RFP-Chk2. (C) RFP-Chk2ΔFHA does not localise to mitotic structures. (D) RFP-FHA localises to spindle poles, kinetochores. FHA domain
tagged with RFP is similar to RFP-Chk2. Scale bar, 10 μm. (E) Quantification of lagging chromosomes during anaphases and telophases in HuS0gen
cells stably expressing Chk2(KD), Chk2ΔFHA and Chk2FHA mutants. Chk2 FHA mutant significantly reduces the number of lagging chromosomes as
a result of the dominant negative effect towards endogenous Chk2. Mean±SD; n=400 anaphases and telophases. *p<0.01versus control. CENP-H,
centromere protein.
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the FHA is responsible for the observed mislocalisation
(figure 7C). Indeed, the FHA domain tagged with RFP loca-
lised to mitotic structures similar to RFP-Chk2 (figure 7D).
Along these lines, we can conclude that the FHA domain is
required for proper Chk2 localisation to mitotic structures.
Furthermore, we analysed the effects of the several Chk2
mutants on lagging chromosomes. Interestingly, transfection of
HuS0gen with Chk2 FHA domain significantly reduced the
number of lagging chromosomes (figure 7E). This result sug-
gests a dominant negative effect of Chk2 FHA domain towards
endogenous Chk2.
Rb phosphorylation contributes to defective mitoses in HuS
cells
An important point raised by defective mitoses-related DNA
damage as observed in this study is why the cells do not sense
signals deployed to curb cell proliferation, as normally the
growth of cultured diploid cells is halted by chromosome misse-
gregation. In HCC, p53 deficiency has been described to partici-
pate in the development of CIN; however, the relevance of p53
to HCC initiation, progression or both remains an area of active
investigation.2 Therefore, the basal level of p53 in HCT116,
Huh7, HuS30gen and HuS0gen was investigated. As shown in
Figure 8 P53 and phosphorylated retinoblastoma (Rb) expression in HCT116, HuS30gen and HuS0gen. (A) Representative immunoblot out
of three independent experiments showing the protein levels of p53 in HCT116, Huh7, HuS30gen and HuS0gen cells. In the same blot are
represented p53 expression levels of HuS0gen cells after treatment with DNA-damaging agent 5-fluorouracil (5-FU, 1 mM). (B)
Representative images of HCT116, Huh7 and HuS30gen cells fixed and stained with an antibody directed against the mutated codon TGT at
position 220 of p53 protein. Huh7 cells, previously characterised as p53 mutated,30 are used as positive control. (C) Representative
immunoblot out of three independent experiments showing the protein levels of Rb and phosphorylated Rb, p-Rb (Ser807/811), in HCT116,
HuS30gen and HuS0gen cells. (D, E and F) Mitoses of asynchronously growing HCT116, HuS30gen and HuS0gen cells stained with the
antibody specific for phosphorylated Rb and analysed by fluorescence microscopy; p-Rb (Ser807/811) red; chromosomes (Hoescht 33342,
blue). Scale bar, 10 mm.
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figure 8A, p53 was expressed in Huh7 and at low level in
HuS30gen cells. HuS0gen cells did not express p53 in basal
conditions; however, treatment of the cells with 5-fluorouracil, a
DNA-damaging agent, triggered a strong p53 protein expres-
sion. Based on these findings, we assume that p53 expression
may be a late event in HuS cells, as a result of several defective
mitoses.19 Furthermore, mutated p53 was not present in
HCT116 and HuS30gen cells in contrast to Huh7 cells that we
used as a positive control (figure 8B).30
The possible involvement of the retinoblastoma protein Rb
was evaluated since several studies have described Rb as an
important regulator of cell division.31 Specifically, Rb phos-
phorylation determines Rb inactivation and leads to defective
mitoses.31 Therefore, we evaluated the protein expression levels
of phospho-Rb (Ser807/811) in HCT116, HuS0gen cells and
HuS30gen. As shown in figure 8C, HuS30gen cells express
higher levels of phospho-Rb (Ser807/811) in comparison to
HuS0gen cells. Moreover, HCT116 (figure 8D), HuS30gen
(figure 8E) and HuS0gen (figure 8F) exhibited a localisation of
phospho-Rb (Ser807/811) at the chromosomal level. Taken
together, these findings suggest that in HuS30gen Rb phosphor-
ylation is required to sustain mitotic activity which leads to
mitotic defects and DNA damage.
DISCUSSION
The neoplastic evolution of HCC proceeds through a multistep
histological process that is less well defined than that of other
cancer types. Hyperplastic nodules of regenerating hepatocytes
have normal karyotype and represent a potential first step
towards HCC. These lesions can progress to dysplastic nodules,
which have abnormal chromosome features including numerical
and structural alterations. These dysplastic nodules can evolve
to HCC marked with recurrent regions of copy number change
and allelic imbalances.3 4 Loss of certain tumour suppressors or
gain of specific oncogenes promote cell division as shown in
many previous studies.25 32 We demonstrate that this coincides
with defective mitoses which can cause DNA damage. This
scenario is conceivable considering that massive deregulation of
mitosis is incompatible with cell survival and can even be
tumour suppressive.33 Therefore, subtle rather than massive
mitotic defects are expected to underlie CIN in HCC, allowing
a tolerable level of chromosome defects. To support this view,
we have provided evidence in this study that hepatocarcinogen-
esis with lagging chromosomes elicits the expression of DNA
damage response protein Chk2. Thus, the overexpression of
Chk2 and its mislocalisation within structures of the mitotic
spindle contribute to sustain cell division and chromosomes mis-
segregation.34–36 This forms a self-perpetuating mechanism
causing DNA damage (figure 9).
We have also found that functional Rb inactivation is neces-
sary but not sufficient to trigger chromosome missegregation.
Indeed, phosphorylation of Rb deregulates transcription factor
E2F, and well-characterised targets of E2F include multiple
genes whose products are required to maintain cell division.37–
39 The integrity of chromosomal DNA is under constant sur-
veillance throughout the cell division. Surprisingly, the fact that
a deregulated functional Chk2 itself might cause per se CIN
through abnormal spindle localisation is intriguing, as the role
Figure 9 A proposed schema illustrating the mechanism by which checkpoint kinase 2 (Chk2) overexpression and mislocalisation sustains defective
mitoses throughout hepatic tumorigenesis. Mitotic errors represented by lagging chromosomes cause DNA damage and overexpress Chk2 in
genetically unstable cells. Chk2 and phosphorylated forms of Chk2 mislocalise within the mitotic structures in the presence of DNA damage
contributing to increase the numbers of lagging chromosomes. FHA, forkhead associated; SCD, SQ/TQ cluster domain.
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of Chk2 in the maintenance of genetic stability has mainly been
ascribed to its function in DNA damage checkpoint signalling.
When DNA damage occurs, Chk2 is first activated in the
nucleus during interphase, spreads to the cytoplasm and localises
to the various mitotic structures because of the phosphopeptide-
binding ability of the FHA domain.40 During DNA damage,
chromosomes accumulate a number of phosphoproteins around
DNA damage sites.41 Chk2 may bind to specific phosphoproteins
through the FHA domain forming numerous chromosomal foci
and trap Chk2 to the structures. When this FHA domain is
deleted, the molecule is excluded from the mitotic chromosomes
and therefore does not mislocalise to kinetochores, spindle poles
and midbody as was demonstrated in figure 7. Moreover, Chk2
localisation to the kinetochores and midbody region suggests that
Chk2 may directly affect spindle assembly function, similar to
Aurora B kinase,42 but only when DNA damage exists. The data
obtained in this study fit a model whereby abnormal expression
of Chk2 and Aurora B kinase disrupts the sensitive balance of
mitotic proteins, which in turn undermines faithful chromosome
segregation.34 If the relative expression levels of the proteins
involved in the quality control of the machinery which ensures
chromosome segregation fidelity is disrupted by mitotic errors
and DNA damage, the resulting imbalance could further com-
promise chromosome segregation accuracy.
Since Chk2 overexpression can induce oligomerisation and
cis/trans phosphorylation of regulatory residues,43 44 one possibil-
ity is that local enrichment of Chk2 at kinetochores and midbody
regions facilitates Chk2 oligomerisation and activation. This
mechanism may alter regulation of Chk2-dependent processes
such as centrosome function, cell cycle progression and chromo-
some segregation. The discovery of a role for Chk2 in HCC, its
association with DNA damage and CIN may have potential diag-
nostic and prognostic significance. Importantly, grading hetero-
geneity inside a tumour is frequently observed and may
significantly limit diagnosis and choice of treatment. This study
suggests that stratification of patients with HCC according to
CIN status and/or DNA damage may be useful to minimise the
confounding effects of tumour CIN status in clinical trials. Along
these lines, we propose that the diagnostic and prognostic value
of Chk2 should be further verified in prospective clinical trials.
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